Bimekizumabe em pacientes com artrite psoriática, sem tratamento biológico: Um estudo de fase 3, randomizado, duplo-cego, controlado por placebo (BE OPTIMAL)

Lancet. 2023 doi: 10.1016/S0140-6736(22)02302-9

This study showed that bimekizumab treatment resulted in clinically meaningful and consistent improvements across multiple measures in bDMARD-naïve patients with active PsA. It aimed to assess the efficacy and safety of bimekizumab in patients with active PsA who were naive to bDMARDs.

Following on from this publication, further publications will report data up to Week 52 to assess the safety and efficacy of bimekizumab in PsA.

Keywords:


Publication thumbnail: Bimekizumabe em pacientes com artrite psoriática, sem tratamento biológico: Um estudo de fase 3, randomizado, duplo-cego, controlado por placebo (BE OPTIMAL)
LinkedIn